[go: up one dir, main page]

ITMI910491A0 - IMMONOTOXIN FROM ANTI-CDS MONOCLONAL ANTIBODIES - Google Patents

IMMONOTOXIN FROM ANTI-CDS MONOCLONAL ANTIBODIES

Info

Publication number
ITMI910491A0
ITMI910491A0 IT91MI491A ITMI910491A ITMI910491A0 IT MI910491 A0 ITMI910491 A0 IT MI910491A0 IT 91MI491 A IT91MI491 A IT 91MI491A IT MI910491 A ITMI910491 A IT MI910491A IT MI910491 A0 ITMI910491 A0 IT MI910491A0
Authority
IT
Italy
Prior art keywords
immonotoxin
monoclonal antibodies
cds
cds monoclonal
antibodies
Prior art date
Application number
IT91MI491A
Other languages
Italian (it)
Inventor
Giulia Porro
Daniela Modena
Fiorenzo Stirpe
Gianni Gromo
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Priority to ITMI910491A priority Critical patent/IT1249051B/en
Publication of ITMI910491A0 publication Critical patent/ITMI910491A0/en
Priority to AU12088/92A priority patent/AU1208892A/en
Priority to PCT/EP1992/000338 priority patent/WO1992014491A1/en
Priority to EP92904825A priority patent/EP0577612A1/en
Publication of ITMI910491A1 publication Critical patent/ITMI910491A1/en
Application granted granted Critical
Publication of IT1249051B publication Critical patent/IT1249051B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ITMI910491A 1991-02-26 1991-02-26 IMMUNOTOXIN FROM ANTI-CD5 MONOCLONAL ANTIBODIES IT1249051B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITMI910491A IT1249051B (en) 1991-02-26 1991-02-26 IMMUNOTOXIN FROM ANTI-CD5 MONOCLONAL ANTIBODIES
AU12088/92A AU1208892A (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies
PCT/EP1992/000338 WO1992014491A1 (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies
EP92904825A EP0577612A1 (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI910491A IT1249051B (en) 1991-02-26 1991-02-26 IMMUNOTOXIN FROM ANTI-CD5 MONOCLONAL ANTIBODIES

Publications (3)

Publication Number Publication Date
ITMI910491A0 true ITMI910491A0 (en) 1991-02-26
ITMI910491A1 ITMI910491A1 (en) 1992-08-26
IT1249051B IT1249051B (en) 1995-02-11

Family

ID=11358745

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI910491A IT1249051B (en) 1991-02-26 1991-02-26 IMMUNOTOXIN FROM ANTI-CD5 MONOCLONAL ANTIBODIES

Country Status (4)

Country Link
EP (1) EP0577612A1 (en)
AU (1) AU1208892A (en)
IT (1) IT1249051B (en)
WO (1) WO1992014491A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
AU2018374283A1 (en) 2017-11-29 2020-06-04 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
JP2022530026A (en) 2019-04-24 2022-06-27 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング Amatoxin antibody drug conjugate and its use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363799A (en) * 1979-03-20 1982-12-14 Ortho Pharmaceutical Corporation Monoclonal antibody to human T cells, and methods for preparing same
FR2577135B1 (en) * 1985-02-13 1989-12-15 Sanofi Sa LONG-TERM ACTION IMMUNOTOXINS COMPRISING A GLYCOPEPTITIDE CONSTITUENT MODIFYING RIBOSOMES MODIFIED ON ITS POLYSACCHARIDE PATTERNS
EP0214995B1 (en) * 1985-03-04 1990-12-27 Dana Farber Cancer Institute Immunotoxin and method of making
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
EP0397798A4 (en) * 1988-02-03 1991-10-30 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
EP0407399A4 (en) * 1988-02-03 1991-06-19 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions
WO1989011871A1 (en) * 1988-06-01 1989-12-14 Cetus Corporation One-step chromatographic purification of immunotoxin conjugates using a thiophilic matrix

Also Published As

Publication number Publication date
WO1992014491A1 (en) 1992-09-03
IT1249051B (en) 1995-02-11
EP0577612A1 (en) 1994-01-12
AU1208892A (en) 1992-09-15
ITMI910491A1 (en) 1992-08-26

Similar Documents

Publication Publication Date Title
CY2006001I1 (en) HUMANIZED HEREGULIN ANTIBODY
FI930580L (en) TRI- OCH TETRAVALENSISKA MONOPECIFIKA ANTIGEN BINDANDE PROTEINER
NO924279D0 (en) LYOPHILIZED, MONOCLONAL ANTIBODY PREPARATION
DE68914244D1 (en) Monoclonal antibody.
DK145493D0 (en) ANTIBODY
DK666389D0 (en) MONOCLONAL ANTIBODY
FI960567L (en) Monoclonal antibody that induces apoptosis
FI935970L (en) TUMOER/KOLHYDRATANTIGENSPECIFIK MONOCLONAL ANTIKROPP SAMT CELLINJE
DE3854502D1 (en) AGAINST HIV-ANTIGENT SPECIFIC MONOCLONAL ANTIBODIES.
FI945865L (en) Monoclonal antibodies directed against glycoprofen P
EP0580859A4 (en) Anti-eda monoclonal antibody
EP0578515A3 (en) Humanized monoclonal antibodies.
NO920523D0 (en) IGE-RECEPTOR ANTIBODY
EP0506523A3 (en) Monoclonal antibodies
NO894444L (en) ANTI-FUCOSYL CERAMIDE MONOCLONAL ANTIBODY.
ITMI910491A0 (en) IMMONOTOXIN FROM ANTI-CDS MONOCLONAL ANTIBODIES
FI934963L (en) CTAA 81AV78, ANTIGEN SOM IGENKAENNS AV MONOCLONAL 87AV78-HUMANANTIKROPP
DK474189A (en) MONOCLONAL ANTIBODY
NO890116D0 (en) MONOCLONAL ANTIBODIES.
DE69023717D1 (en) Monoclonal antibody.
FI893928A (en) MONOCLONAL MOTCROPPAR.
EP0508282A3 (en) Anti-idiotypic monoclonal antibodies
ITRM920223A0 (en) MONOCLONAL ANTI-IDIOPIC ANTIBODIES DIRECTED AGAINST ANTI-TNF ANTIBODIES.
NO924803D0 (en) TUMOR-RELATED MONOCLONAL ANTIBODY 88BV59
ZA912136B (en) Anti-oncostatin m monoclonal antibodies

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960227